From the microbial colony to the infection in man: The case of Pseudomonas aeruginosa, therapeutic importance;De la colonie microbienne à l'infection chez l'homme: Le cas de Pseudomonas aeruginosa, importance thérapeutique

Antibiotiques

Volumn 6, Issue 4, 2004, Pages 241-248

  Meybeck, A ^a   Fantin, Bruno ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Pseudomonas aeruginosa; Resistance; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFOPERAZONE; CEFPIROME; CEFSULODIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; IMIPENEM; ISEPAMICIN; MACROLIDE; MEROPENEM; MONOBACTAM DERIVATIVE; NOVOBIOCIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TAZOBACTAM; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM IDENTIFICATION; DRUG CHOICE; DRUG POTENTIATION; DRUG TARGETING; GRAM NEGATIVE INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA;

EID: 10244266460     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1294-5501(04)94271-9     Document Type: Article

References (74)

1. Pitt TL. Epidemiological typing of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1988 ; 7 : 238-47.
2. The International Pseudomonas aeruginosa Typing Study Group. A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominently from patients with cystic fibrosis. J Infect Dis 1993 ; 169 : 134-42.
3. Talon D, Caillaux V, Thouverz M, et al. Discriminatory power and usefulness of pulsed-field gel electrophoresis in epidemiological studies of Pseudomonas aeruginosa. J Hosp Infect 1996 ; 32 : 135-45.
4. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000 ; 45 : 433-6.
5. Benz R, Hancock RE. Properties of the large ion-permeable pores formed from protein F of Pseudomonas aeruginosa in lipid bilayer membranes. Biochim Biophys Acta 1981 ; 646 : 298-308.
6. Poole K. Multidrug efflux pumps and anti-microbial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001 ; 3: 255-64.
7. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995 ; 8 : 557-84.
8. Vahaboglu H, Ozturk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey; a nationwide multicenter study. Antimicrob Agents Chemother 1997 ; 41 : 2265-9.
9. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999 ; 5 : 865-79.
10. Poirel L, Girlich D, Naas T, et al. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integrin-located gene. Antimicrob Agents Chemother 2001 ; 45 : 447-53.
11. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000 ; 3 : 489-95.
12. Masuda N, Sakagawa E, Ohya S, et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000 ; 45 : 433-6.
13. Ochs MM, Mccusker MP, Bains M, et al. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999 ; 43 : 1085-90.
14. Mayer KH. Review of epidemic aminoglycoside resistance worldwide. Am J Med 1986 ; 80 : 56-64.
15. Lambert T, Collatz E. Etat actuel de la sensibilitaé des bactéries à Gram négatif aux aminosides en France: entérobactéries, Pseudomonas, Acinetobacter, distribution des mécanismes de résistance. Lettre de l'infectiol 1996 (hors-série janv.): 10-16.
16. Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 1998 ; 4 : 257-61.
17. Tang HB, Dimango E, Bryan R, et al. Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Infect Immun 1996 ; 64 : 37-43.
18. Comolli JC, Hauser AR, Waite L, et al. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 1999 ; 67 : 3625-30.
19. De Bentzmann S, Roger P, Dupuit F, et al. Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immun 1996 ; 64 : 1582-8.
20. Takase H, Nitanai H, Hoshino K, et al. Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun 2000 ; 68 : 1834-9.
21. May TB, Shinabager D, Maharaj R, et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991 ; 4 : 191-206.
22. May TC, Chakrabarty AM. Pseudomonas aeruginosa genes and enzymes of alginate synthesis. Trends Microbiol 1994 ; 2 : 151-7.
23. Hastie AT, Hingley ST, Higgins ML, et al. The effect of rhamnolipid hemolysin of Pseudomonas aeruginosa on respiratory epithelium. Am Rev Respir Dis 1987 ; 135 : 513-14.
24. Vasil ML, Graham LM, Ostroff RM, et al. Phospholipase C: molecular biology and contribution to the pathogenesis of Pseudomonas aeruginosa. Antibiot Chemother 1991 ; 44 : 34-47.
25. Woods DE, Crys SJ, Friedman RL, et al. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun 1982 ; 39 : 1223-8.
26. Blackwood LL, Stone RM, Iglewski BH, et al. Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect Immun 1983 ; 39 : 198-201.
27. Woods DE, Sokol PA. Use of a transposon mutants to assess the role of exoenzyme S in chronic pulmonary disease due to Pseudomonas aeruginosa. Eur J Clin Microbiol 1985 ; 4 : 163-9.
28. Allewelt M, Coleman FT, Grout M, et al. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000 ; 68 : 3998-4004.
29. Roychoudhury S, Sakai K, Chakrabarty AM. Algr2 is an ATP/GTP-dependent protein kinase involved in alginate synthesis by Pseudomonas aeruginosa. Proc Natl Acad Sci USA 1992 ; 89 : 2659-63.
30. Hobbs M, Collie ES, Free PD, et al. PilS and PilR, a two-component transcriptional regulatory system controlling expression of type 4 fimbriae in Pseudomonas aeruginosa. Mol Microbiol 1993 ; 7 : 669-82.
31. Ritchings BW, Almira EC, Lory S, et al. Cloning and phenotypic characterization of fleS and fleR new response regulators of Pseudomonas aeruginosa which regulate motility and adhesion to mucin. Infect Immun 1995 ; 63 : 4868-76.
32. Anba J, Bidaud M, Vasil ML, et al. Nucleotide sequence of the Pseudomonas aeruginosa PhoB gene, the regulatory gene for the phosphate regulon. J Bacteriol 1990 ; 172 : 4685-9.
33. Dean CR, Neshat S, Poole K. Pfer, an enterobactin-responsive activator of ferric enterobactin receptor gene expression in Pseudomonas aeruginosa. J Bacteriol 1996 ; 178 : 5361-9.
34. Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol 1991 ; 173 : 3000-9.
35. Pearson JP, Gray KM, Passador L, et al. Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes. Proc Natl Acad Sci USA 1994 ; 91 : 197-201.
36. Gambello MJ, Kaye S, Iglewski BH. LasR of Pseudomonas aeruginosa is a transcriptional activator of the alcaline protease gene (apr) and an enhancer of exotoxin A expression. Infect Immun 1993 ; 61 : 1180-4.
37. Pearson JP, Pesci EC, Iglewski BH. Roles of Pseudomonas aeruginosa las and rhl quorum sensing in control of elastase and rhamnolipid biosynthesis genes. J Bacteriol 1997 ; 179 : 5756-67.
38. Ochsner UA, Fiechter A, Reiser J. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J Bacteriol 1994 ; 176 : 2044-54.
39. Pearson JP, Passador L, Iglewski BH, et al. A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa. Proc Natl Sci USA 1995 ; 92 : 1490-4.
40. Pearson JP, Feldman M, Iglewski BH, et al. Pseudomonas aeruginosa cell to cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun 2000 ; 68 : 4331-4.
41. Morissette C, Skamene E, Gervais F. Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice. Infect Immun 1995 ; 63 : 1718-24.
42. Sapru K, Stotland PK, Stevenson MM. Quantitative and qualitative differences in bronchoalveolar inflammatory cells in Pseudomonas aeruginosa-resistant and - susceptible mice. Clin Exp Immunol 1999 ; 115 : 103-9.
43. Standiiford TJ, Tsai WC, Mehrad B, et al. Cytokines as targets of immunotherapy in bacterial pneumonia. J Lab Clin Med 2000 ; 135 : 129-38.
44. Chmiel JF, Konstan MW, Knesebeck JE, et al. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 1999 ; 160 : 2040-7.
45. Miyazaki H, Broaddus CV, Wierner-Kronish J, et al. The effects of two antiinflammatory pretreatments on bacterial-induced lung injury. Anesthesiology 1999 ; 90 : 1650-62.
46. Morissette C, Francoeur C, Darmond-Zwaig C, et al. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect Immun 1996 ; 64 : 4884-92.
47. Cavallo JD, Leblanc F, Fabre R, et al. Surveillance de la sensibilité de Pseudomonas aeruginosa aux antibiotiques en France et distribution des mécanismes de résistance aux bêtalactamines: étude GERPB 1999. Pathol Biol 2001 ; 49 : 1-6.
48. Jaffar-Bandjee MC, Ladzunski A, Bally M, et al. Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J Clin Microbiol 1995 ; 33 : 924-9.
49. Storey DG, Ujack EE, Rabin HR. Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis. Infect Immun 1998 ; 66 : 2521-8.
50. Muhlebach MS, Stewart PW, Leigh MW, et al. Quantification of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999 ; 160 : 186-91.
51. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997 ; 156 : 1197-204.
52. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995 ; 152 : 2111-8.
53. Karpati F, Hjelte L, Wretlind B. TNF-α and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis 2000 ; 32 : 75-9.
54. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa : our worst nightmare ? Clin Infect Dis 2002 ; 34 : 634-40.
55. Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus : clinical significance and therapeutic approaches. J Antimicrob Chemother 1990 ; 26 : 165-79.
56. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003 ; 37 : 154-60.
57. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993 ; 328 : 1740-6.
58. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000 : 162 : 328-30.
59. Hoiby N, Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990 ; 45 : 22-7.
60. De Groot R, Smith A. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987 ; 13 : 228-53.
61. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003 ; 168 : 918-51.
62. Auerbach HS, Williams M, Kikpatrick JA, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985 ; 2 : 686-8.
63. Eigen HR, Rosentein BJ, Fitz Simmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995 ; 126 : 515-23.
64. Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial of inhaled budenoside in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997 ; 156 : 1190-6.
65. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001 : 31 : 464-73.
66. Yanagihara K, Tomono K, Imamura Y, et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemoth 2002 ; 49 : 867-70.
67. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004 ; 125 : 62S-69S.
68. Barghouthi S, Guerdoud LM, Speert DP. Inhibition by dextran of Pseudomonas aeruginosa adherence on epithelial cells. Am J Respir Crit Care Med 1996 ; 154 : 1788-93.
69. Bryan R, Feldman M, Jawetz SC, et al. The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection. J Infect Dis 1999 ; 179 : 1449-58.
70. Cole AM, Liao H, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002 ; 169 : 6985-91.
71. Travis SM, Conway B, Zabner J, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Crit Care Med 1999 ; 20 : 872-9.
72. Ramsey B, Rodman D, Redman R, et al. Phase I safety and tolerability study of ascending multiple doses of aerosolized iseganan HCL solution (IB-367) in adults with cystic fibrosis. Pediatr Pulmonol 2001 ; 32 : A263.
73. Coban Y, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolones resistance in Pseudomonas aeruginosa isolates. Chemotherapy 2004 ; 50 : 22-6.
74. Smith RS, Iglewski BH. Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J Clin Invest 2003 ; 112 : 1460-65.